The hemodynamic and electrophysiologic alterations induced by ionic contrast agents during cardiac angiography are well described. Recently nonionic contrast agents have become available for cardiac angiography. To evaluate the safety of these new agents, a doubleblind randomized study was performed comparing a new nonionic agent (iopamidol) with a commonly used ionic contrast agent . Eighty-one patients undergoing left ventriculography and coronary angiography were included; 41 received iopamidol and 40 received sodium meglumine diatrizoate .
The hemodynamic and electrophysiologic alterations induced by ionic contrast agents during cardiac angiography are well described. Recently nonionic contrast agents have become available for cardiac angiography. To evaluate the safety of these new agents, a doubleblind randomized study was performed comparing a new nonionic agent (iopamidol) with a commonly used ionic contrast agent (Renografin-76). Eighty-one patients undergoing left ventriculography and coronary angiography were included; 41 received iopamidol and 40 received sodium meglumine diatrizoate (Renografin-76).
After left ventriculography, there was a decrease in the arterial pressure with both contrast agents. However, the severity and the duration of hypotension were both significantly greater with Renografin-76 compared with the new non ionic agent (p < 0.001). After selective injections of the coronary arteries, electrocardiographic Numerous animal and human studies (1-18) have documented the deleterious effects of ionic contrast media on the myocardium immediately after contrast ventriculography and coronary angiography, Decreases in systemic arterial pressure and myocardial contractility and alterations in the ventricular pressure-volume relation after the use of ionic contrast agents are well described ( I A-IS), Although the intensity and duration of these changes are known. the mechanisms responsible for these alterations of myocardial function remain controversial. The contribution of various factors. such as contrast-induced hypocalcemia. osmolality of the agent or a direct effect of the contrast molecule or analysis demonstrated that the increase in the QT interval (p < 0.0002) and the changes in both the ST segment and T wave amplitude (p < 0.001) were significantly greater in the Renografin-76 group compared with the iopamidol group. During coronary angiography, 8 of the 40 patients receiving Renografin-76 required temporary pacing for sinus pauses of 2.5 seconds or more, and 2 of the 40 also developed ventricular fibrillation. None of the 41 patients receiving iopamidol had these complications.
This report demonstrates that the electrocardiographic changes, the severity and duration of hypotension and the incidence of serious arrhythmias are significantly greater with Renografin-76 than with iopamidol. Thus, this new nonionic agent appears to enhance the safety of cardiac angiography. (J Am Coli Cardiol 1985; 5:250-8) anion. to these hemodynamic and physiologic alterations is unclear (5.7.11-13.15.19-27) . Sodium meglumine diatrizoate (Renografin-76) is a commonly used contrast agent for cardiac angiography. Several studies (1.8. 15.17.20) have demonstrated the adverse effects of this standard ionic agent on myocardial function. metabolism and electrophysiology. Metrizamide was the first commercially available nonionic contrast agent. Animal and human studies (15.20.28-32) demonstrated that its adverse hemodynamic and physiologic effects were significantly less than those of ionic agents. In addition. it reduced the discomfort experienced by the patient during intravascular angiography (32) . However, metrizamide is unstable in aqueous solution; therefore, it must be reconstituted from the lyophilized form immediately before intravascular injection. Recently, nonionic contrast agents that are hydrolytic ally stable have been developed and are being evaluated for use in coronary angiography (33) (34) (35) (36) (37) (38) (39) (40) .
The purpose of this investigation was to evaluate one of these new nonionic agents. iopamidol. in human subjects in a randomized double-blind study. The electrocardio- To evaluate the safety of these new agents, a doubleblind randomized study was performed comparing a new nonionic agent (iopamidol) with a commonly used ionic contrast agent (Renografin-76). Eighty-one patients undergoing left ventriculography and coronary angiography were included; 41 received iopamidol and 40 received sodium meglumine diatrizoate (Renografin-76).
After left ventriculography, there was a decrease in the arterial pressure with both contrast agents. However, the severity and the duration of hypotension were both significantly greater with Renografin-76 compared with the new nonionic agent (p < 0.001). After selective injections of the coronary arteries, electrocardiographic Numerous animal and human studies (1-18) have documented the deleterious effects of ionic contrast media on the myocardium immediately after contrast ventriculography and coronary angiography. Decreases in systemic arterial pressure and myocardial contractility and alterations in the ventricular pressure-volume relation after the use of ionic contrast agents are well described (I A-IS). Although the intensity and duration of these changes are known. the mechanisms responsible for these alterations of myocardial function remain controversial. The contribution of various factors, such as contrast-induced hypocalcemia, osmolality of the agent or a direct effect of the contrast molecule or analysis demonstrated that the increase in the QT interval (p < 0.0002) and the changes in both the ST segment and T wave amplitude (p < 0.001) were significantly greater in the Renografin-76 group compared with the iopamidol group. During coronary angiography, 8 of the 40 patients receiving Renografin-76 required temporary pacing for sinus pauses of 2.5 seconds or more, and 2 of the 40 also developed ventricular fibrillation. None of the 41 patients receiving iopamidol had these complications.
This report demonstrates that the electrocardiographic changes, the severity and duration of hypotension and the incidence of serious arrhythmias are significantly greater with Renografin-76 than with iopamidol. Thus, this new nonionic agent appears to enhance the safety of cardiac angiography. (J Am Coli Cardiol 1985; 5:250-8) anion, to these hemodynamic and physiologic alterations is unclear (5,7,11-13.15,19-27) . Sodium meglumine diatrizoate (Renografin-76) is a commonly used contrast agent for cardiac angiography. Several studies (\.8, 15, 17, 20) have demonstrated the adverse effects of this standard ionic agent on myocardial function, metabolism and electrophysiology. Metrizamide was the first commercially available nonionic contrast agent. Animal and human studies (\5.20,28-32) demonstrated that its adverse hemodynamic and physiologic effects were significantly less than those of ionic agents. In addition, it reduced the discomfort experienced by the patient during intravascular angiography (32) . However, metrizamide is unstable in aqueous solution; therefore, it must be reconstituted from the lyophilized form immediately before intravascular injection. Recently, nonionic contrast agents that are hydrolytically stable have been developed and are being evaluated for use in coronary angiography (33) (34) (35) (36) (37) (38) (39) (40) .
The purpose of this investigation was to evaluate one of these new nonionic agents, iopamidol. in human subjects in a randomized double-blind study. The electrocardio-graphic and hemodynamic alterations induced by this new agent during left ventriculography and selective coronary angiography were measured and compared with those Induced by Renografin-76.
Methods
Patient selection. All patients undergoing left ventriculography and selective coronary angiography at the San Francisco Veterans Administration Medical Center were eligible for this study except for I) patients with a history of adverse reactions to contrast media or iodine compounds, 2) patients with bleeding disorders, 3) patients with creatinine clearance below 25 mllmin, and 4) patients receiving intravascular or orally absorbable contrast material within I week of the study.
The study was of a randomized double-blind design for comparison of iopamidol and sodium meglumine diatrizoate (Renografin-76) as the contrast agent used for left ventriculography and selective coronary angiography. Iopamidol and Renografin-76 both contain 37% iodine. The viscosities of iopamidol and Renografin-76 are similar at 37°C, 9.4 cp and 8.4 cp, respectively.
Procedure. All patients received oral diazepam ( 10 mg) as premedication. No medications were withheld before the catheterization. No patient received atropine. Electrocardiographic leads I and II were monitored continuously during the procedure. An 8F USCI sheath was placed in the femoral artery. For the treatment of bradyarrhythmias or complete heart block which may develop during coronary angiography, a temporary pacing catheter was inserted through a femoral venous sheath and positioned at the apex of the right ventricle. For asystolic episodes lasting 2.5 seconds or more, pacing was performed at 60 beats/min until the patient's intrinsic rhythm returned. The left ventriculogram was performed using a 7F Cordis high flow pigtail catheter; 0.5 ml/kg of contrast medium was injected at 12 mils. The amount of contrast agent injected for the left ventriculogram was 40.5 :i: 5.7 ml in the iopamidol group and 37.4 :i: 4.9 ml in the Renografin-76 group. Left ventricular volumes and ejection fraction were calculated using a calibrated grid and the method of Kennedy et al. (41) . The electrocardiogram, left ventricular pressure and femoral artery pressure were recorded continuously for 6 seconds before the left ventriculogram and for the first 2 minutes after the injection. In all patients, the left ventriculogram preceded the selective injections of the right and left coronary arteries. Similarly, the electrocardiogram and aortic pressure were recorded before and for the first 2 minutes after the first selective injection of the right and left coronary arteries. All recordings were made at a strip chart speed of 100 mm/s. There were no test injections of contrast agent preceding the left ventriculogram or the first selective injection of the coronary arteries. Immediately after the procedure, each patient was GERTZ ET AL.
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NON IONIC CONTRAST CARDIAC ANGIOGRAPHY asked to grade on a 0 to 10 scale subjective feelings of pain and warmth that occurred during and after the contrast injections.
The cineangiograms were reviewed by an independent observer with regard to quality of contrast, definition and opacification of coronary vessels and were graded as poor, adequate, good or excellent.
Blood for determination of urea nitrogen and serum creatinine was obtained at baseline (before angiography) and at 24 and 48 hours after the procedure. If the values were abnormal at 48 hours, these tests were repeated I week after angiography and, if abnormal, repeated until the values returned to baseline levels. The protocol was approved by the Human Research Committees of the University of California and the Veterans Administration Medical Center at San Francisco. Informed written consent was obtained from each patient.
Statistics. All hemodynamic and electrocardiographic variables were analyzed by repeated measures analysis of variance using Tukey's tests to determine whether there was a difference between the changes induced by the two contrast agents (42) . The unpaired t test was used to determine whether there was a difference between the hemodynamic and electrocardiographic variables of the iopan;idol and Renografin-76 groups at baseline. The chi-square test was used to compare discrete variables. The nonparametric variables such as cineangiographic quality and subjective response of the patients to the contrast agent were compared using the Mann-Whitney test. The data in the text and tables are presented as mean :i: I standard deviation. The mean values :i: I standard error are shown in the figures.
Results
Patient characteristics. The study group consisted of 81 male patients. Seventy-nine patients underwent left ventriculography and selective coronary angiography for symptoms of ischemic heart disease and two underwent the procedure for evaluation of valvular heart disease. Forty-one patients received iopamidol and 40 received Renografin-76.
The patient characteristics in these two groups are listed in Tahle I. A coronary lesion was considered significant if 75% or more of the cross-sectional luminal area of the vessel was obstructed. There was no significant difference between the two groups in the number of patients with significant left main lesions and with no, one, two or three vessel disease. Two patients receiving Renografin-76 had aortic valve disease; one had significant aortic regurgitation requiring valve replacement and the other had mild aortic stenosis. One patient in the iopamidol group had significant aortic stenosis requiring valve replacement. In each group, there was one patient with mild mitral regurgitation.
Indexes ollefi ventricular function are also listed in Table  I . There was no significance difference in ejection fraction, 
Methods
Procedure. All patients received oral diazepam ( 10 mg) as premedication. No medications were withheld before the catheterization. No patient received atropine. Electrocardiographic leads I and II were monitored continuously during the procedure. An 8F USCI sheath was placed in the femoral artery. For the treatment of bradyarrhythmias or complete heart block which may develop during coronary angiography, a temporary pacing catheter was inserted through a femoral venous sheath and positioned at the apex of the right ventricle. For asystolic episodes lasting 2.5 seconds or more. pacing was performed at 60 beats/min until the patient's intrinsic rhythm returned. The left ventriculogram was performed using a 7F Cordis high flow pigtail catheter; 0.5 ml/kg of contrast medium was injected at 12 mils. The amount of contrast agent injected for the left ventriculogram was 40.5 :i: 5.7 ml in the iopamidol group and 37.4 :i: 4.9 ml in the Renografin-76 group. Left ventricular volumes and ejection fraction were calculated using a calibrated grid and the method of Kennedy et al. (41) . The electrocardiogram, left ventricular pressure and femoral artery pressure were recorded continuously for 6 seconds before the left ventriculogram and for the first 2 minutes after the injection. In all patients. the left ventriculogram preceded the selective injections of the right and left coronary arteries. Similarly. the electrocardiogram and aortic pressure were recorded before and for the first 2 minutes after the first selective injection of the right and left coronary arteries. All recordings were made at a strip chart speed of 100 mm/s. There were no test injections of contrast agent preceding the left ventriculogram or the first selective injection of the coronary arteries. Immediately after the procedure, each patient was asked to grade on a 0 to 10 scale subjective feelings of pain and warmth that occurred during and after the contrast injections.
The cineangiograms were reviewed by an independent observer with regard to quality of contrast. definition and opacification of coronary vessels and were graded as poor. adequate. good or excellent.
Blood for determination of urea nitrogen and serum creatinine was obtained at baseline (before angiography) and at 24 and 48 hours after the procedure. If the values were abnormal at 48 hours. these tests were repeated I week after angiography and, if abnormal. repeated until the values returned to baseline levels. The protocol was approved by the Human Research Committees of the University of California and the Veterans Administration Medical Center at San Francisco. Informed written consent was obtained from each patient.
Results
The patient characteristics in these two Rroups are listed in Tahle I. A coronary lesion was considered significant if 75% or more of the cross-sectional luminal area of the vessel was obstructed. There was no significant difference between the two groups in the number of patients with significant left main lesions and with no. one. two or three vessel disease. Two patients receiving Renografin-76 had aortic valve disease; one had significant aortic regurgitation requiring valve replacement and the other had mild aortic stenosis. One patient in the iopamidol group had significant aortic stenosis requiring valve replacement. In each group, there was one patient with mild mitral regurgitation.
Indexes oj"lefi ventricular function are also listed in Table  I . There was no significance difference in ejection fraction. Data are presented a, mean :±: I standard deviation. CAD = coronary artery disease: NS = no significant difference between the iopamidol and Renografin-76 groups.
left ventricular end-diastolic volume index and baseline left ventricular end-diastolic pressure between the two groups.
The medications received hy the patients hellJre the anxioxraphic study are listed in Tahle 2. There was no significant difference in the types of medications prescribed for the patients in the two groups.
The haseline (hellJre contrast medium) systolic arterial pressure, le.lf ventricular end-diastolic pressure and electrocardioxraphic data for these two xroups ol paticnts arc xivcn in Tahle 3. There was no significant difference in any of these measurements at baseline between the two groups.
Hemodynamic alterations. The baseline (before contrast medium) systolic arterial pressure was 146 ± 22 mm Hg in the Renografin-76 group and 141 ± 24 mm Hg in the iopamidol group (p = NS). After left ventriculography, there was a decrease in the arterial pressure in both groups (Fig. 1 ). The average decrease in systolic pressure was 48 ± 14 mm Hg in the Renografin-76 group and 19 ± II mm Hg in the iopamidol group (p < 0.001). The duration of the decrease in systolic pressure (decrease in systolic pressure > 10% of control) was 45 ± 25 seconds in the Renografin-76 group compared with 9 ± 10 seconds in the iopamidol group (p < 0.00 I). Thus, not only was the decrease in arterial pressure greater after Renografin-76 but also the duration of these changes was significantly longer compared with iopamidol. The change in left ventricular end-diastolic pressure induced by ventriculography is also shown in Figure 1 . After injection of Renografin-76, the average increase in end-diastolic pressure at 90 seconds after the ventriculogram was 9 ± 7 mm Hg compared with 1 ± 5 mm Hg for iopamidol. This difference was highly significant (p < 0.001).
Thc systolic artcrial prcssurc durinx the control period and alter the .first selcctive injection ()l the riXht and le.li coronary arteries is shown in Fixure 2. There was no significant difference between the two groups in the arterial pressure during the control period. After selective injection of either the right or the left coronary artery, arterial pressure did not change in the iopamidol group but decreased significantly in the Renografin-76 group (p < 0.001).
Electrocardiographic changes. Figure 3 compares the electrocardiographic changes induced by selective contrast injections of the left and right coronary arteries and left ventriculography in the Renografin-76 and iopamidol groups. Data are shown for the control period and for the 60 second period after the contrast injection. With selective left coronary injection, there was a marked prolongation of the QT interval. from 394 ± 32 to 482 ± 56 ms, in the Renografin-76 group (p < 0.001), but only a slight increase, from 386 ± 33 to 393 ± 36 ms, in the iopamidol group (p = NS). A repeated measures analysis of variance showed that there 252 GERTZ ET AL. NONIONIC CONTRAST CARDIAC ANGIOGRAPHY left ventricular end-diastolic volume index and baseline left ventricular end-diastolic pressure between the two groups.
The medications received by the patients be/fIre the anxioxraphic study are listed in Table 2 . There was no significant difference in the types of medications prescribed for the patients in the two groups.
The baseline (be/f)re contrast medium) systolic arterial pressure, left ventricular end-diastolic pressure and electrocardiof,?raphic data F)r these two xroups ol patients are xiven in Table 3 . There was no significant difference in any of these measurements at baseline between the two groups.
Hemodynamic alterations. The baseline (before contrast medium) systolic arterial pressure was 146 ± 22 mm Hg in the Renografin-76 group and 141 ± 24 mm Hg in the iopamidol group (p = NS). After left ventriculography, there was a decrease in the arterial pressure in both groups (Fig. I) of the decrease in systolic pressure (decrease in systolic pressure > 10% of control) was 45 ± 25 seconds in the Renografin-76 group compared with 9 ± 10 seconds in the iopamidol group (p < 0.00 I). Thus, not only was the decrease in arterial pressure greater after Renografin-76 but also the duration of these changes was significantly longer compared with iopamidol. The change in left ventricular end-diastolic pressure induced by ventriculography is also shown in Figure I . After injection of Renografin-76, the average increase in end-diastolic pressure at 90 seconds after the ventriculogram was 9 ± 7 mm Hg compared with I ± 5 mm Hg for iopamidol. This difference was highly significant (p < 0.00 I).
The systolic arterial pressure durinx the control period and alter the .first selective injection ()l the riXht and le.li coronary arteries is shown in Fixure 2. There was no significant difference between the two groups in the arterial pressure during the control period. After selective injection of either the right or the left coronary artery, arterial pressure did not change in the iopamidol group but decreased significantly in the Renografin-76 group (p < 0.001).
Electrocardiographic changes. Figure 3 compares the electrocardiographic changes induced by selective contrast injections of the left and right coronary arteries and left ventriculography in the Renografin-76 and iopamidol groups. Data are shown for the control period and for the 60 second period after the contrast injection. With selective left coronary injection, there was a marked prolongation of the QT interval. from 394 ± 32 to 482 ± 56 ms, in the Renografin-76 group (p < 0.001), but only a slight increase, from 386 ± 33 to 393 ± 36 ms, in the iopamidol group (p = NS). A repeated measures analysis of variance showed that there All electrocardiographic variahles were measured in lead II One millivolt = 10 n1l11. NS no slgnilieant difference hetween the iopamidol and Renogralil1-76 groups. Data are presented as mean + 1 standard deviation. was a significant difference in the prolongation of the QT interval produced by two contrast agents (p < 0.0001). At the end of the 60 second period. there was still a significant increase in the QT interval in the Renografin-76 group compared with the control value (p < 0.001). and a significant difference between the two contrast agent groups (p < 0.00 I).
Selective injections of the right coronary artery produced a similar change in the QT interval; the difference between was a significant difference in the prolongation of the QT interval produced by two contrast agents (p < 0.0001). At the end of the 60 second period. there was still a significant increase in the QT interval in the Renografin-76 group compared with the control value (p < 0.001). and a significant difference between the two contrast agent groups (p < 0.00 I).
Selective injections of the right coronary artery produced a similar change in the QT interval; the difference between electrocardiographic analysis of lead II demonstrated significant ST segment depre~sion from 0.0 ± 0.5 to -0,9 ± I, I Iilm (p < 0.00 I) and marked T wave inversion from an amplitude of 1.4 ± 1,2 to -2,2 ± 2,6 mm (p < (LOOI) (Fig, 3) , At the end of 60 seconds. there was still a significant decrease in T wave amplitude compared with the control value in the Reriografin-76 group (p < (U)OI). With iopamidol. there was ST segment depression from 0,0 ± 0,3 to -0,3 ± 0,6 mm at 5 seconds after the contrast injection (p < 0,0(5). but there was no significant change in T wave amplitude, A repeated measures analysis of variance showed that there was a significant difference in the ST segment and T wave amplitude response for the two contrast agents (p < 0,05 and p < (U)OOI. respectively),
With the left corollary injections there was a significant elevation in the ST segment and a significant increase in T wave amplitude in lead II with Renografin-76, With iopamidol. there was no significant change in these two variables (Fig, 3) . Serious arrhythmias. Two of the patients in the Renografin-76 group developed ventricular fibrillation during selective injection of the right coronary artery: the arrhythmia was immediately treated with electrical cardioversion and there were no iate sequelae in either patient. There were no episodes of ventricular tachycardia or fibrillation in the iopamidol group.
There was 0 siRnijiCllflt hut hrier tJecreose ill the hearl rate immediately after injections of I:Jbth the right and left coronary arteries with Renografin-76 ( Fig. 3) . whereas with iopamidol there was no significant change in the heart rate. All patients in this study had a temporary pacing catheter placed in the right ventricle which wa~ used for periods of asystole lasting 2.5 seconds or more. Eight of the 40 patients receiving Renografin-76 required pacing during the coronary injections. However. none of the 41 patients in the iopamidol group was paced during the procedure. This difference in the development of serious bradyarrhythmias during coronary injections is significant (p < 0.(1).
Chest pain. It is not uncommon for patients to experience transient chest pain and feelings of warmth during and immediately after selective contrast injections of the coronary arteries and during left ventriculography. After the procedure. each patient was asked to grade these subjective feelings of pain and warrhth that occurred during angiography. Thirty-three of the 40 patiertts receiving Renografin-76 had no chest pain during the irltravascular bolus injection for the left ventriculogram. Likewise. 37 of the 41 patients in the iopamidol group had no pain. There was no significant difference between the two groups for chest pain induced by the left ventriculogram. However. on a scale of 0 to 10 for the sensation of warmth associated with the left ventriculogram. the mean score was 7.0 ± 2.5 for the Reno- (5) . In the Renografin-76 group. the mean score for pain during the selective coronary angiography was 3.1 ± 3.0 and the score for warmth was 2.8 ± 2.7. In comparison. the mean scores for the iopamidol group were 0.8 ± 1.6 and 1.1 ± 2.0. respectively. The differences for both pain and warmth during coronary angiography were significant (p < (LOS). In most patients. the chest pain associated with the contrast injection was very transient and required no treatment. However. 13 of the patients treated with Renografin-76 required nitroglycerin for their chest pain associated with coronary angiography, Only five of the iopamidol-treated patients had chest pain requiring treatment with nitroglycerin during the study.
Other side effects. Two of the patients receiving Renografin-76 developed nausea and vomiting after contrast injection. None of the patients in the iopamidol group had gastrointestinal symptoms during or after the procedure.
There was flO difference in the mean creatinine clearance hetweefl the two groups; the mean value for the calculated creatinine clearance was 81 ± 23 ml/min in the patients treated with Renografin-76 and 85 ± 25 mllmin in the iopamidol-treated patients. Two patients receiving Renografin-76 had deterioration of their renal function after angiography. as defined by a 0.5 mg/dl increase in serum creatinine. In these patients, the creatinine increased from 1.3 and 1.2 mg/dl (control) to 2.3 and 2.6 mg/dl. respectively, 48 hours after angiography. In the iopamidol group. only one patient had a similar increase in serum creatinine from 1.2 to 1.7 mg/dl. In all three patients. the deterioration in renal function was transient.
Quality of cineangiograms. Both contrast agents contain 370 mg iodine/ml and produced very good to excellent visuali/.ation of the coronary anatomy. We could not detect a difference in the cineangiographic quality of the left ventriculograms and the selective coronary angiograms between iopamidol and Renografin-76.
Discussion
Safety of cardiac angiography. Morbidity and mortality associated with selective coronary angiography and left ventriculography have decreased in the last decade (43) (44) (45) . Many of the remaining complications are directly related to the contrast medium. There is a decrease in systemic arterial pressure and an increase in left ventricular end-diastolic pressure immediately after an intravascular bolus injection of an ionic contrast medium for the left ventriculogram (5.7-9.13.31.34.35 
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With riRht coronan' arten' injections or Renografin-76. electrocardiographic analysis of lead II demonstrated signiticant ST segment depre~sion from 0,0 ± 0,5 to -0.9 ± 1.1 Jilm (p < 0.00 I) and marked T wave inversion from an amplitude of 1.4 ± 1,2 to -2.2 ± 2.6 mm (p < (l.001) ( Fig. 3) . At the end of 60 seconds. there was still a significant decrease in T wave amplitude compared with the control value in the Renogratin-76 group (p < 0,(01). With iopamidol, there was ST segment depression from 0.0 ± 0.3 to -0.3 ± 0.6 mm at 5 seconds after the contrast injection (p < 0.0(5), but there was no significant change in T wave amplitude, A repeated measures analysis of variance showed that there was a signiticant difference in the ST segment and T wave amplitude response for the two contrast agents (p < 0,05 and p < 0,0001. respectively),
With the left coronary injections there was a significant elevation in the ST segment and a significant increase in T wave amplitude in lead II with Renogratin-76. With iopamidol, there was no significant change in these two variables (Fig. 3) .
Serious arrhythmias. Two of the patients in the Renogratin-76 group developed ventricular tibrillation during selective injection of the right coronary artery: the arrhythmia was immediately treated with electrical cardioversion and there were no iate sequelae in either patient. There were no episodes of ventricular tachycardia or tibrillation in the iopamidol group.
There was a significant hut hrier tJecrease in the !lmrt rate immediately after injections of I:Jbth the right and left coronary arteries with Renogratin-76 ( Fig. 3) . whereas with iopamidol there was no signiticant change in the heart rate. All patients in this study had a temporary pacing catheter placed in the right ventricle which wa~used for periods of asystole lasting 2.5 seconds or more. Eight of the 40 patients receiving Renogratin-76 required pacing during the coronary injections. However. none of the 41 patients in the iopamidol group was paced during the procedure. This difference in the development of serious bradyarrhythmias during coronary injections is significant (p < 0.01).
Chest pain. It is not uncommon for patients to experience transient chest pain and feelings of warmth during and immediately after selective contrast injections of the coronary arteries and during left ventriculography. After the procedure. each patient was asked to grade these subjective feelings of pain and warrhth that occurred during angiography. Thirty-three of the 40 patiertts receiving Renogratin-76 had no chest pain during the irltravascular bolus injection for the left ventriculogram. Likewise, 37 of the 41 patients in the iopamidol group had no pain. There was no significant difference between the two groups for chest pain induced by the left ventriculogram. However, on a scale of 0 to 10 for the sensation of warmth associated with the left ventriculogram, the mean score was 7.0 ± 2.5 for the Renogratin-76 group and 4,2 ± 2.3 for the iopamidol group; this difference was significant (p < (l05).
During selective coronan' angiography. 25 of the 40 patients treated with Renogratin-76 had chest pain, whereas only II of the 41 iopamidol-treated patients had pain (p < 0.005). In the Renogratin-76 group, the mean score fix pain during the selective coronary angiography was 3.1 ± 3,0 and the score for warmth was 2,8 ± 2.7. In comparison, the mean scores for the iopamidol group were 0.8 ± 1.6 and \.\ ± 2.0, respectively. The differences for both pain and warmth during coronary angiography were signiticant (p < (l.05). In most patients, the chest pain associated with the contrast injection was very transient and required no treatment. However, 13 of the patients treated with Renogratin-76 required nitroglycerin for their chest pain associated with coronary angiography. Only five of the iopamidol-treated patients had chest pain requiring treatment with nitroglycerin during the study.
There was no difference in the mean creatinine clearance hetween the two groups; the mean value for the calculated creatinine clearance was 81 ± 23 ml/min in the patients treated with Renografin-76 and 85 ± 25 mllmin in the iopamidol-treated patients. Two patients receiving Renogratin-76 had deterioration of their renal function after angiography, as defined by a 0.5 mg/dl increase in serum creatinine. In these patients, the creatinine increased from 1.3 and 1.2 mg/dl (control) to 2,3 and 2.6 mg/dl, respectively. 48 hours after angiography. In the iopamidol group, only one patient had a similar increase in serum creatinine from 1.2 to 1.7 mg/dl. In all three patients, the deterioration in renal function was transient.
Quality of cineangiograms. Both contrast agents contain 370 mg iodine/ml and produced very good to excellent visuali/.ation of the coronary anatomy. We could not detect a difference in the cineangiographic quality of the left ventriculograms and the selective coronary angiograms between iopamidol and Renogratin-76.
Discussion
Safety of cardiac angiography. Morbidity and mortality associated with selective coronary angiography and left ventriculography have decreased in the last decade (43) (44) (45) . Many of the remaining complications are directly related to the contrast medium. There is a decrease in systemic arterial pressure and an increase in left ventricular end-diastolic pressure immediately after an intravascular bolus injection of an ionic contrast medium for the left ventriculogram (5,7-9.13,31,34,35) . Selective coronary injections of these ionic agents are associated with bradyarrhythmias, prolongation of the QRS complex. increase in the QT interval, marked shifts in the ST segment and T wave changes ( 1-3. 10,29,31 ,34.46). Development of contrast agents that are less toxic to the myocardium than these standard ionic agents should enhance the safety of angiographic procedures.
Animal studies (15.28-31.38) have shown that the new nonionic agents arc associated with fewer hemodynamic and electrocardiographic changes compared with ionic contrast media. Measurements of myocardial contractility have shown that these new agents have a small positive inotropic effect as opposed to the negative inotropic effects of the ionic agents (15.20.33.35) . These non ionic agents have been evaluated in several human studies (32,34,39.40) , and their results corroborate the findings of the animal studies, suggesting that these new agents are safer.
This is the first large study that compares iopamidol and Renografin-76 in human subjects in a double-blind randomized fashion. Our data demonstrate that the hemodynamic and electrocardiographic changes induced by contrast left ventriculography and coronary angiography were significantly less when the nonionic agent. iopamidol. was compared with a standard ionic contrast medium. The incidence and severity of bradyarrhythmias and systemic hypotension were greater with Renografin-76 compared with iopamidol. Prolongation of the QT interval. widening of the QRS complex and ST and T wave changes were also significantly greater in the Renografin-76 group compared with the iopam idol group. These findings indicate that iopamidol is less toxic to the myocardium compared with Renografin-76.
Ventricular fibrillation. Ventricular fibrillation is one of the most serious complications associated with coronary angiography and is directly associated with injections of contrast agent. Although there is no direct relation between development of ventricular fibrillation and changes in the QT interval. prolongation of the QT interval is considered a risk factor for ventricular arrhythmia (46) (47) (48) (49) . In this study, the increase in the QT interval was significantly greater with Renografin-76 than with iopamidol (p < 0.0(02). If there were a direct relation between prolongation of QT interval and ventricular fibrillation. one might expect a higher incidence of ventricular fibrillation in the Renografin-76 group. In our study, 2 of the 40 patients in the Renografin-76 group developed ventricular fibrillation during selective coronary angiography, whereas none of the 41 patients receiving iopamidol had this complication. Although the number of patients in this study is too small to determine the true incidence of ventricular fibrillation for each contrast agent. our data suggest that the incidence of ventricular fibrillation may be higher for Renografin-76 than for iopamidol. Using Renografin-76 as the contrast agent. the incidence in our laboratory of ventricular tachycardiafibrillation is 1.5%. This was determined in 260 consecutive cases petformed after the completion of this double-blind study.
Heterogeneity of depolarization and repolarization within adjacent areas of the myocardium is one of the proposed JACC Vol. 5. No.2 February 1985:250-8 mechanisms of contrast-induced ventricular fibrillation. Franz et al. (50) measured indexes of depolarization and repolarization during the coronary injections of iopamidol and Renografin-76 in dogs. They found that Renografin-76 caused a significantly greater prolongation of the monophasic action potential compared with iopamidol. Their findings also suggest that the risks of ventricular arrhythmias are higher with Renografin-76 than with iopamidol.
Biochemical data. We (17) and Visioli et al. (18) have demonstrated that contrast ventriculography with Renografin-76 induces changes in myocardial metabolism. Recently (51) . we have investigated the myocardial metabolic effects of iopamidol and have shown that the decrease in myocardial lactate extraction that occurs after injection of Renografin-76 did not occur with this new nonionic agent. Using [1- '4 Cllactate as a tracer, we measured the amount of lactate released by the myocardium before and after an injection of Renografin-76 and iopamidol. After injection of Renografin-76, there was a 54 ± 38% increase in myocardial lactate release, whereas after iopamidol there was no significant change in the amount of lactate released (52) . These biochemical data suggest that contrast angiography with the standard ionic agents induces myocardial cellular ischemia and that the newer non ionic agent. iopamidoJ, does not produce these changes.
Factors influencing contrast medium toxicity. In addition to the contrast ion or molecule, there are a number of other important differences between these two contrast agents, such as osmolality and cation composition and content. The contribution of these factors to the electrocardiographic and hemodynamic differences observed in this study is unclear. Many reports (5.7,12,13,15,19,20,28,35,53) have indicated that the toxicity of a contrast agent is directly related to the osmolality. The osmolality of Renografin-76 ( 1,680 mosm/kg) is approximately twice that of iopamidol (796 mosm/kg) (34, 36, 38) . Recently, an ionic contrast agent (ioxaglate) has been developed which has an osmolality similar to iopamidol (20, 31, 38, 53) . Tragardh and Lynch (31) compared the effects of ioxaglate, diatrizoate (Renografin-76) and two nonionic compounds during coronary angiography in animals. Their study demonstrated that both nonionic agents were associated with fewer hemodynamic and electrophysiologic changes than the new ionic low osmolality contrast agent. Although osmolality plays an important role in contrast agent toxicity, the study by Tragardh and Lynch (31) suggests that it is not the only factor. The cation composition and content of the contrast agent also appear to be important factors (15, 19, 20, 22, 23, 46, (54) (55) (56) . lopamidol has negligible amounts of sodium compared with 190 mEq/liter in Renografin-76. Renogratin-76 has no calcium and iopamidol contains only negligible amounts of calcium. Contrast agents with varying sodium and calcium contents have been evaluated (15, 20, 22, 23, 56) . Although the addition of calcium appears to decrease the toxicity, the 256 GERTZ ET AL. NONIONIC CONTRAST CARDIAC ANGIOGRAPHY JACC Vol. 5. No.2 February 1985:250-8 are less toxic to the myocardium than these standard ionic agents should enhance the safety of angiographic procedures.
Animal studies (15.28-31.38) have shown that the new nonionic agents are associated with fewer hemodynamic and electrocardiographic changes compared with ionic contrast media. Measurements of myocardial contractility have shown that these new agents have a small positive inotropic effect as opposed to the negative inotropic effects of the ionic agents (15.20.33.35) . These non ionic agents have been evaluated in several human studies (32,34.39.40) . and their results corroborate the findings of the animal studies. suggesting that these new agents are safer.
Ventricular fibrillation. Ventricular fibrillation is one of the most serious complications associated with coronary angiography and is directly associated with injections of contrast agent. Although there is no direct relation between development of ventricular fibrillation and changes in the QT interval. prolongation of the QT interval is considered a risk factor for ventricular arrhythmia (46) (47) (48) (49) . In this study. the increase in the QT interval was significantly greater with Renografin-76 than with iopamidol (p < 0.0002). If there were a direct relation between prolongation of QT interval and ventricular fibrillation. one might expect a higher incidence of ventricular fibrillation in the Renografin-76 group. In our study. 2 of the 40 patients in the Renografin-76 group developed ventricular fibrillation during selective coronary angiography. whereas none of the 41 patients receiving iopamidol had this complication. Although the number of patients in this study is too small to determine the true incidence of ventricular fibrillation for each contrast agent. our data suggest that the incidence of ventricular fibrillation may be higher for Renografin-76 than for iopamidol. Using Renografin-76 as the contrast agent. the incidence in our laboratory of ventricular tachycardiafibrillation is 1.5%. This was determined in 260 consecutive cases performed after the completion of this double-blind study.
Heterogeneity of depolarization and repolarization within adjacent areas of the myocardium is one of the proposed mechanisms of contrast-induced ventricular fibrillation. Franz et a!. (50) measured indexes of depolarization and repolarization during the coronary injections of iopamidol and Renografin-76 in dogs. They found that Renografin-76 caused a significantly greater prolongation of the monophasic action potential compared with iopamidol. Their findings also suggest that the risks of ventricular arrhythmias are higher with Renografin-76 than with iopamidol.
Biochemical data. We (17) and Visioli et a!. (18) have demonstrated that contrast ventriculography with Renografin-76 induces changes in myocardial metabolism. Recently (51) . we have investigated the myocardial metabolic effects of iopamidol and have shown that the decrease in myocardial lactate extraction that occurs after injection of Renografin-76 did not occur with this new nonionic agent. Using [1- '4 Cjlactate as a tracer, we measured the amount of lactate released by the myocardium before and after an injection of Renografin-76 and iopamidoJ. After injection of Renografin-76. there was a 54 ± 38% increase in myocardial lactate release. whereas after iopamidol there was no significant change in the amount of lactate released (52) . These biochemical data suggest that contrast angiography with the standard ionic agents induces myocardial cellular ischemia and that the newer nonionic agent, iopamidol. does not produce these changes.
Factors influencing contrast medium toxicity. In addition to the contrast ion or molecule. there are a number of other important differences between these two contrast agents. such as osmolality and cation composition and content. The contribution of these factors to the electrocardiographic and hemodynamic differences observed in this study is unclear. Many reports (5,7,12,13,15,19,20,28.35,53) have indicated that the toxicity of a contrast agent is directly related to the osmolality. The osmolality of Renografin-76 ( 1.680 mosm/kg) is approximately twice that of iopamidol (796 mosm/kg) (34.36,38) . Recently, an ionic contrast agent (ioxaglate) has been developed which has an osmolality similar to iopamidol (20,31.38,53) . Tragardh and Lynch (31) compared the effects of ioxaglate. diatrizoate (Renografin-76) and two nonionic compounds during coronary angiography in animals. Their study demonstrated that both noniohic agents were associated with fewer hemodynamic and electrophysiologic changes than the new ionic low osmolality contrast agent. Although osmolality plays an important role in contrast agent toxicity. the study by Tragardh and Lynch (31) suggests that it is not the only factor. The cation composition and content of the contrast agent also appear to be important factors (15,19,20.22,23,46,54-56) . lopamidol has negligible amounts of sodium compared with 190 mEg/liter in Renografin-76. Renogratin-76 has no calcium and iopamidol contains only negligible amounts of calcium. Contrast agents with varying sodium and calcium contents have been evaluated (15,20.22.23,56) . Although the addition of calcium appears to decrease the toxicity, the entire cardiodepressant effect of the contrast medium is not eliminated. Further studies are needed to elucidate the mechanisms for the differences in the toxicity we observed between iopamidol and Renografin-76.
Clinical implications. This study has shown that the incidence of malignant bradyarrhythmias and the severity and duration of hypotension after left ventriculography and coronary angiography is significantly less with iopamidol than with the standard ionic agent. Renogratin-76. The incidence of ventricular fibrillation may also be less with iopamidol compared with Renografin-76. Other electrocardiographic and hemodynamic variables measured in this study indicate that iopamidol is less toxic to the myocardium. Therefore. this nonionic agent appears to increase the safety of cardiac angiography. In addition. the discomfort experienced by the patient was considerably less with iopamidol compared with the ionic agent. The cineangiographic quality of the two contrast agents was similar. Increasing the safety of cardiac angiography without compromising excellent cineangiographic results makes this new nonionic contrast agent. iopamidol. superior to the standard ionic agents.
The cost of this new nonionic contrast medium will probably be greater than the standard ionic contrast agents. Further studies are needed to address the cost/benefit ratio of these new agents. Although the costs may preclude their use in all patients undergoing angiography. we believe that patients at high risk. such as those with impending myocardial infarction, unstable angina, impaired ventricular function or recurrent ventricular arrhythmias. will benefit greatly through the use of these nonionic agents in cardiac angiography. 29 Fehruary 19K5: 250-S GERTZ lOT AL. NON IONIC CONTRAST CARDIAC ANGIOGRAPHY 257 entire cardiodepressant effect of the contrast medium is not eliminated. Further studies are needed to elucidate the mechanisms for the differences in the toxicity we observed between iopamidol and Renogratin-76.
Clinical implications. This study has shown that the incidence of malignant bradyarrhythmias and the severity and duration of hypotension after left ventriculography and coronary angiography is significantly less with iopamidol than with the standard ionic agent. Renografin-76. The incidence of ventricular fibrillation may also be less with iopamidol compared with Renografin-76. Other electrocardiographic and hemodynamic variables measured in this study indicate that iopamidol is less toxic to the myocardium. Therefore, this nonionic agent appears to increase the safety of cardiac angiography. in addition. the discomfort experienced by the patient was considerably less with iopamidol compared with the ionic agent. The cineangiographic quality of the two contrast agents was similar. increasing the safety of cardiac angiography without compromising excellent cineangiographic results makes this new nonionic contrast agent. iopamidoL superior to the standard ionic agents.
The cost of this new nonionic contrast medium will probably be greater than the standard ionic contrast agents. Further studies are needed to address the cost/benefit ratio of these new agents. Although the costs may preclude their use in all patients undergoing angiography. we believe that patients at high risk, such as those with impending myocardial infarction, unstable angina, impaired ventricular function or recurrent ventricular arrhythmias, will benefit greatly through the use of these nonionic agents in cardiac angiography.
